Sarepta Therapeutics

Yahoo Finance • 6 days ago

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?

We recently published a list of Pulse of the Market: Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other Wednesday’s top performers. The stock m... Full story

Yahoo Finance • 8 days ago

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, March 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRP... Full story

Yahoo Finance • 8 days ago

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges On Tuesday, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-r... Full story

Yahoo Finance • last month

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Participants Vincent Anzalone; Investor Relations; Arrowhead Pharmaceuticals Inc Christopher Anzalone; President, Chief Executive Officer, Director; Arrowhead Pharmaceuticals Inc Bruce Given; Chief Operating Officer; Arrowhead Pharmaceu... Full story

Yahoo Finance • last month

2 Growth Stocks to Buy Hand Over Fist in February

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring. Two healthcare stocks that may... Full story

Yahoo Finance • 2 months ago

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc. (SRPT)'s share was trading at... Full story

Yahoo Finance • 6 months ago

Exploring TeraWulf And Two Other High Growth Tech Stocks

The market is up 1.2% over the last week and has risen 30% over the past 12 months, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high-growth tech stocks like TeraWulf can be crucial for investo... Full story

Yahoo Finance • 7 months ago

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

CAMBRIDGE, Mass., August 30, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Mor... Full story

Yahoo Finance • 8 months ago

This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes

This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes During earnings season, big banks are often among the first companies to unveil their quarterly financial results. But rather t... Full story

Yahoo Finance • 10 months ago

Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?

We recently compiled the list of the 10 Best Fast Growth Stocks To Buy according to the hedge funds using the latest sentiment data. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands agai... Full story

Yahoo Finance • 11 months ago

Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) just released its quarterly report and things are looking bullish. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 10% highe... Full story

Yahoo Finance • 11 months ago

10 Unstoppable Stocks That Will Make You Richer

In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out... Full story

Yahoo Finance • last year

Billionaire Ray Dalio and Insiders Love These 10 Stocks

In this article, we will take a detailed look at Billionaire Ray Dalio and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ray Dalio and Insiders Love These 5 Stocks. Investors are on tente... Full story

Yahoo Finance • last year

Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcom... Full story

Yahoo Finance • last year

Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight

Strengths: Proprietary RNA-targeted technology platforms and a robust pipeline of gene therapies. Weaknesses: Ongoing operating losses and intense competition in the biopharmaceutical industry. Opportunities: Expansion of commercial distri... Full story

Yahoo Finance • last year

Sarepta Rebounded. Its Gene Therapy Is Back on Course.

The future of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy looked grim two months ago. There’s been a 180 since. Continue reading... Full story

Yahoo Finance • last year

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., January 02, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd Annual J.P. Morgan H... Full story

Yahoo Finance • last year

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story

Yahoo Finance • last year

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

Application includes request for Priority Review from the US FDA Sarepta has also submitted the EMBARK postmarketing requirement to the FDA seeking conversion of the ELEVIDYS accelerated approval to traditional approval CAMBRIDGE, Mass.,... Full story